Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

44.59 +0.45 (+1.02%)
Streaming Delayed Price Updated: 10:07 AM EDT, Oct 4, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,004,384
Open 44.25
Bid (Size) 44.59 (4)
Ask (Size) 44.60 (13)
Prev. Close 44.14
Today's Range 44.09 - 44.84
52wk Range 40.94 - 61.71
Shares Outstanding 5,606,688,356
Dividend Yield 3.50%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial
From Pfizer Inc.
Via Business Wire
CFund Capital to Present at Blockchain Expo North America October 5-6
Markham, ON () October 3, 2022 -- CFund is a professional platform integrating investor education, liquidity provision and crypto asset management. 
Via Prodigy
Topics Economy
Exposures Supply Chain

Performance

YTD
-21.29%
-21.29%
1 Month
-2.56%
-2.56%
3 Month
-13.65%
-13.65%
6 Month
-12.47%
-12.47%
1 Year
+5.12%
+5.12%

More News

Read More
Pfizer Completes Acquisition of Biohaven Pharmaceuticals
From Pfizer Inc.
Via Business Wire
Myovant Sciences Rockets After Rejecting Lowball Sumitovant Biopharma Takeover Bid
Via Investor's Business Daily
What Are Whales Doing With Pfizer
Via Benzinga
Pfizer To Supply 6M COVID-19 Therapy Courses To Low Income Countries
Via Benzinga
Top Five Weekend Stock Stories - Sunday, Oct. 2nd
Via Talk Markets
7 S&P 500 Stocks to Sell Before They Die
Via InvestorPlace
4 Blue-Chip Stocks to Sell in October
Via InvestorPlace
Biohaven's ALS Drug Fails To Meet Study Endpoint, Second Therapy To Fail Trials In Recent Months
Via Benzinga
Merck Inks Supply Deal With Sinopharm To Commercialize COVID-19 Pills In China
Via Benzinga
CDC and FDA Misinformation – Retroactive Editing, Erroneous Spontaneous Abortion Rate Calculation, Obfuscation by NEJM
Via Newsworthy
Exposures COVID-19 Product Safety
The Road to Health never ends
Via eTrendy Stock
Exposures COVID-19
As Moderna Grapples With Supply Shortage, FDA Gives Nod To Additional Lots of COVID-19 Booster
Via Benzinga
7 Vaccine Stocks to Sell ASAP Now That the ‘Pandemic’s Over’
Via InvestorPlace
iPhone 14 Popular In China?, Netflix May Lose Comics, Elon Musk's Starlink Slows, Byron Allen Faces $10B Lawsuit And More Top Financial Media Stories Monday, Sept. 26
Via Benzinga
Pfizer/BioNTech Seek FDA Emergency Nod For Updated COVID-19 Shot For Kids Under 11 Years
Via Benzinga
Pfizer CEO Contracts COVID-19 Infection For Second Time
Via Benzinga
Moderna Seeks FDA Approval For Updated COVID-19 Shot For Kids, But Scrambles Supply Challenges
Via Benzinga
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age
From Pfizer Inc.
Via Business Wire
Switzerland To Dispose 10M Expired COVID-19 Vaccine Doses From Moderna
Via Benzinga
Pfizer Resumes Dosing In Phase 3 Hemophilia Gene Therapy Trial Six Months After FDA Lifts Clinical Hold
Via Benzinga
The Worst Thing That Can Happen to the Human Species, is Happening – Dr. Naomi Wolf is Available for Interview
Via Newsworthy
Topics Lawsuit
Exposures COVID-19 Financial Legal
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Here Are Novavax's U.S. Vaccination Numbers — And They're Bleak
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.